Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis.
Authors
Lesniewski-Kmak, KMoiseenko, V
Saunders, Mark P
Wasan, H
Argiles, G
Borg, C
Creemers, G
Fedyanin, M
Glynne-Jones, R
Pfeiffer, P
Punt, C
Stroyakovskiy, D
Ten Tije, A
Van de Wouw, A
Kanehisa, A
Fougeray, R
Busto, N
Amellal, N
Van Cutsem, E
Affiliation
Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, PolandIssue Date
2018-06
Metadata
Show full item recordCitation
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. 2018, 29(Suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdy149.021Type
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy149.021